Actively Recruiting
Evaluating the Safety and Effects of Felzartamab Infusions in Adults with Kidney Transplants Experiencing Late Isolated Microvascular Inflammation
Led by Biogen · Updated on 2026-10-30
81
Participants Needed
51
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are investigating the effects of felzartamab in adults who have received kidney transplants and later developed microvascular inflammation MVI, a condition involving injury to small blood vessels in the transplanted kidney that may signal rejection. This condition can lead to serious kidney problems over time and sometimes occurs without the usual antibodies, known as isolated MVI. The study aims to understand how felzartamab influences inflammation in the transplanted kidney and overall kidney health. Participants will be randomly assigned to receive either felzartamab or a placebo through intravenous IV infusions. The study is divided into two parts Part A lasts 24 weeks, during which neither participants nor researchers know who receives felzartamab or placebo Part B lasts an additional 28 weeks where all participants receive felzartamab openly. Kidney biopsies will take place at the start, Week 24, and Week 52 to evaluate changes in inflammation. Participants will be involved for about one year, undergoing regular kidney biopsies, lab tests, and monitoring for adverse events. Researchers will assess inflammation resolution, kidney function, immune activity, and overall health. Safety is closely monitored through biopsies and lab results, with adverse events recorded throughout the trial to ensure thorough evaluation of felzartamabs effects.
CONDITIONS
Brief Title
A Study to Learn About the Effects of Felzartamab Infusions in Adults With Kidney Transplants Who Have Late Isolated Microvascular Inflammation
Research Team
U
US Biogen Clinical Trial Center
G
Global Biogen Clinical Trial Center
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here